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ABSTRACT
Tregitopes are a set of epitopes, derived from IgG, that
bind to MHCII, activate nTregs, and promote tolerance.
We have now confirmed that coadministration of Tregi-
topes with a range of proteins (autoantigens and nomi-
nal antigens, such as OVA) in vitro and in vivo leads to
suppression of T cell and antibody responses to the
test antigens. In this study, we demonstrate that Tregi-
topes are not immunogenic in vivo even when emulsi-
fied with strong adjuvants, such as IFA or CFA. More-
over, in vivo administration of Tregitopes with IFA or
CFA does not induce Th1 or Th2 cytokine expression
under restimulation conditions in vitro. We investigated
tolerance induction by codelivering Tregitopes with
OVA using B cells. When B cells were pulsed with OVA
plus Tregitopes and transferred into naïve mice, we found
that cellular and humoral immune responses to the OVA
were suppressed. As a result of their ability to induce
Tregs and the absence of immunogenicity in the context
of strong adjuvants, Tregitopes might be considered a
novel immunomodulatory approach for the suppression
of immune responses to protein therapeutics (such as
FVIII and mAb), as well as for treatment of autoimmune
diseases. J. Leukoc. Biol. 94: 377–383; 2013.
Introduction
Antigen-specific immunotherapies for tolerance induction are
desirable for autoimmune diseases, transplantation, and al-
lergy, as well as for protein therapeutics that have been associ-
ated with clinical immunogenicity. Tolerance to self-antigens is
controlled through multiple central and peripheral mecha-
nisms. Among them, Tregs play an essential role in controlling
peripheral tolerance [1]. CD4CD25FoxP3 nTregs, once
activated through the TCR, suppress effector T cells through
contact-dependent and -independent mechanisms [2]. Accu-
mulating evidence suggests that nTreg-deficient patients and
animals exhibit severe immune deficiencies and sometimes
lethal inflammatory conditions [3–5]. Therefore, induction or
activation of nTregs may be an ideal approach for therapy of au-
toimmune diseases. One aspect of nTreg immune responses that
remains unresolved is whether their effects are antigen-specific.
Much effort has been made to induce or expand antigen-specific
nTregs for the purpose of immunotherapy. However, because of
the lack of knowledge about the epitopes recognized by nTregs,
no effective strategy has been identified to date.
Several lines of evidence suggest that epitopes for nTregs
exist in IgG. First, high-dose therapeutic IVIg has been widely
used in the clinic to treat multiple autoimmune diseases [6–8].
Whereas several non-Treg-related mechanisms of action of
IVIg have been proposed—such as autoantibody neutraliza-
tion, modulation of expression and function of FcRs, interfer-
ence with activation of complement and the cytokine network,
and modulation of DC maturation and function [9]—addi-
tional studies suggest that IVIg also works through Tregs. For
example, in an animal model for multiple sclerosis (EAE),
prophylactic infusion of IVIg expanded Tregs and prevented
disease development in a Treg-dependent manner [10]. Sec-
ondly, IgG Fc-containing fusion proteins have been used to
induce tolerance in animal models for T1D, EAE, and hemo-
philia A, via protein or gene therapy [11–14]. In gene therapy
animal models of hemophilia A and T1D, we have shown that
IgG fusion-induced tolerance depends on nTregs [15, 16].
Tregitopes were first identified when mAb was screened for
T cell epitope content. The modulation of the anti-self im-
mune response to antibody hypervariable regions (CDRs) has
been the subject of intensive study. To shed light on this phe-
nomenon, we scanned human and murine IgG sequences for
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T cell epitopes using the EpiMatrix and ClustiMer software
algorithms [17]. Several highly conserved, promiscuous T
helper epitopes were identified in the Fc and Fab regions of
IgG. These were defined as Tregitopes, based on their ability
to suppress T cell responses in vitro [17]. hTregitope167 and
hTregitope289 contain multiple HLA class II-binding motifs
and have been shown to bind to murine and human MHC
[17, 18]. In vitro studies demonstrated that these two Tregi-
topes could activate nTregs and expand inducible Tregs [17].
We have also demonstrated that mTregitope167 and mTregi-
tope289 induced expansion of FoxP3 Tregs in a transgenic
(DO11.10) mouse model and suppressed the antigen-specific
response [19, 20]. More importantly, when diabetes-prone
NOD mice were treated with mTregitope167 and mTregi-
tope289 at the onset of diabetes, hyperglycemia was reversed.
These results suggest that Tregitopes have excellent immuno-
suppressive properties that are possibly a result of their ability
to activate Tregs [20]. Overall, our data indicate that Tregi-
topes comprise an excellent candidate for immunomodulation
in the context of autoimmunity and/or transplantation.
In this study, we investigated the immunogenicity of Tregi-
topes, focusing on mTregitope167 (stronger H-2b-binding affin-
ity) and mTregitope289 (stronger H-2d-binding affinity). These
peptides exhibited limited or no immunogenicity in vivo, even
when emulsified with CFA or IFA. We also showed that Tregi-
topes are capable of suppressing immune-responsiveness to OVA
when codelivered with the antigen via B cells. Our results indi-
cate that as an immune-suppression reagent, Tregitopes have very
weak immunogenicity that allows for the observed immunomodu-
latory effect and for their therapeutic potential.
MATERIALS AND METHODS
Mice
C57BL/6 and BALB/c mice were purchased from The Jackson Laboratory
(Bar Harbor, ME, USA). All recipient animals were used at 5–6 weeks of
age and housed in pathogen-free microisolator cages in our animal facility.
Peptides and antibodies
mTregitope167, mTregitope289, and OVA323–339 peptides were synthesized by
New England Peptide (Gardner, MA, USA). Anti-IFN- capture and detection
antibodies were purchased from BD Biosciences (San Jose, CA, USA).
B cell purification, Tregitope pulsing, and tolerance
induction
B cells were purified from spleens to 95% homogeneity with anti-T cell
antibody cocktails (anti-Thy1, anti-CD4, and anti-CD8), followed by comple-
ment (Low-Tox-M; Cedarlane, Burlington, Ontario, Canada). Purified B
cells were cultured with RPMI-1640 medium (Gibco; Invitrogen, Carlsbad,
CA, USA), supplemented with 5% FBS, 2 mM L-glutamine, and 2-ME. B
cells were prestimulated with 5 g/ml bacterial LPS (Escherichia coli 055:B5;
Sigma, St. Louis, MO, USA) overnight. LPS-stimulated B cells were incu-
bated with 100 g/ml mTregitope167 and mTregitope289, 1 mg/ml OVA
protein, or 100 g/ml mTregitope167 and mTregitope289 plus 1 mg/ml
OVA protein for 2 h at 37°C. Cells were washed three times with PBS be-
fore transfer of 107 cells/mouse into syngeneic mice i.p. Seven to 10 days
following injection, animals were immunized in a hind footpad and base of
the tail with 25 g OVA323–339 peptide emulsified in CFA. Two weeks later,
mice were euthanized, sera were collected, and draining inguinal and pop-
liteal LNs were removed. Cellular and humoral responses were examined
by Elispot and ELISA, respectively. Elispot plates were coated with 1 g/ml
anti-IFN- capture antibody overnight. LN cells were seeded at 5  105/
well in a 96-well plate in the presence of the indicated concentration of
OVA323–339 peptide. After 48 h, Elispot plates were developed using biotin-
ylated anti-IFN- antibody, followed by HRP-conjugated anti-rat IgG. Elispot
plates were read on an ImmunoSpot Elispot counter (Cellular Technolo-
gies, Shaker Heights, OH, USA). Antibody titers were determined by the
endpoint dilution method. Serial 3-fold dilutions were made in PBS  2%
BSA. The endpoint titer represents the highest dilution of sample with an
OD450 reading greater than twofold of blank control.
Measurement of immune response
Tregitopes (mixture of mTregitope289 and mTregitope167) were emulsi-
fied with IFA or CFA and injected into C57BL/6 or BALB/c mice in one
footpad. Each mouse was injected with 12.5 g mTregitope167 and
mTregitope289, with the same amount of OVA323–339 peptide (known
binder for MHC IAb and IAd) used as a control. Two weeks later, draining
popliteal and inguinal LNs were removed and assayed for cell proliferation
by [3H] thymidine incorporation. LN cells were seeded at 5  105/well in
a 96-well plate in the presence of the indicated concentration of antigen.
After 48 h, cultures were pulsed with 1 Ci/well [3H] thymidine and incu-
bated for an additional 16–20 h. Cells were then harvested on glass fiber
filters, and incorporated [3H] thymidine was detected via liquid scintilla-
tion counting in a Microbeta2 Plate reader (Perkin Elmer, Boston, MA,
USA). Data are expressed as cpm (by subtraction of the background with-
out antigen). Before pulsing cell cultures with [3H] thymidine, superna-
tants from a 2-g/ml antigen culture were collected for a cytokine assay.
Production of IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p40, and IFN- was deter-
mined by ELISA in the Cytokine Core Laboratory at the University of Mary-
land (Baltimore, MD, USA).
Real-time PCR
C57BL/6 mice were immunized with a mixture of mTregitope167 and
mTregitope289, OVA323–339, or PBS in IFA in a footpad. Two weeks later,
draining LNs were isolated, and cells were treated in vitro with mTregi-
tope167 and mTregitope289 or OVA323–339 peptide at 2 g/ml. Forty-eight
hours later, total RNA samples were extracted with a PureLink RNA Mini
Kit (Ambion; Life Technologies, Carlsbad, CA, USA), followed by DNAse
treatment (Turbo DNA-free; Ambion; Invitrogen, Life Technologies, Carls-
bad, CA, USA) and transcription into cDNA using the SuperScript VILO
cDNA Synthesis Kit (Life Technologies). FAM probes for detecting the ex-
pression of T-bet, GATA-3, RORt, and Foxp3 were ordered from Life
Technologies (TaqMan Gene Expression assays), and quantitative RT-PCR
(10 min at 95°C and 45 cycles of 10 s at 95°C, 30 s at 60°C, and 1 s at
72°C) was performed in the LightCycler 480 system (Roche, Basel, Switzer-
land). Amplification was done in a total volume of 20 l using TaqMan
Gene Expression Master Mix (Applied Biosystems; Life Technologies). For
each sample, mRNA expression was normalized to the detected Ct value of
GAPDH. The experiment was performed at the Biomedical Instrumenta-
tion Center of the Uniformed Services University of the Health Sciences.
Statistics
Paired or unequal variance one-tailed Student’s t-test statistics were applied
where indicated.
RESULTS
mTregitope167 and mTregitope289 delivered by B cells
suppress immune response to OVA protein in vivo
We showed previously that Tregitopes induce Treg expansion
in a TCR transgenic mouse model and suppress disease pro-
gression in a T1D model [20]. In the latter model, we treated
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NOD mice with Tregitopes emulsified in IFA when the mice
became hyperglycemic and found that Tregitope treatment
could reverse new onset diabetes in the majority of the mice.
As IFA is not an ideal adjuvant for the clinic, in this study, we
first asked whether Tregitopes could be delivered by other
routes for immune suppression. We have used a protocol for
tolerance induction that uses B cells as APCs [21, 22]. This
method of inducing tolerance by retrovirally transduced B
cells with IgG-antigen fusions has been used in a variety of dis-
ease models, such as hemophilia A [15], T1D [16, 23], EAE
[23–25], and experimental autoimmune uveoretinitis [26].
Thus, we hypothesized that antigen-pulsed B cells might also
deliver Tregitopes to effectively induce tolerance in vivo. Splenic B
cells were activated overnight with the TLR agonist LPS and
pulsed with Tregitopes (mTregitope167 and mTregitope289),
OVA protein, or Tregitopes plus OVA protein the following
day. These B cells were then adoptively transferred into naïve,
syngeneic C57BL/6 mice. One week later, recipients were im-
munized with OVA323–339 peptide in CFA in the footpad. Two
weeks later, T cells from draining popliteal and inguinal LNs
were cultured with OVA323–339 peptide for evaluation of cellu-
lar response by IFN- Elispot. In parallel, serum samples were
assayed for anti-OVA IgG titer by ELISA. As shown in Fig. 1A
compared with OVA protein-pulsed B cells, treating mice with
Tregitope-pulsed B cells led to a significant reduction in IFN-
production in the ex vivo restimulation assay. T cells from
mice treated with Tregitopes and OVA protein-pulsed B cells
responded with lower levels of IFN- production than T cells
from mice treated with Tregitope-pulsed B cells alone, suggest-
ing that coadministration of Tregitopes with the target antigen
promotes antigen-specific hyporesponsiveness. The antibody
responses showed the same trend; lower antibody responses
were observed in mice treated with Tregitopes plus OVA pro-
tein (Fig. 1B) compared with mice treated with Tregitopes
alone. Collectively, these data indicate that Tregitope peptides,
delivered by B cells, with and without target antigen, are capa-
ble of inducing hyporesponsiveness.
mTregitope167 and mTregitope289 have no
immunogenicity in vivo
One of the major hurdles preventing some therapeutic pro-
teins from being used in the clinic is their immunogenicity.
For example, recombinant clotting FVIII is used routinely as
replacement therapy in hemophilia A patients. However, up to
30% of patients develop anti-FVIII inhibitory antibodies [27].
The conventional treatment of patients with inhibitory antibod-
ies is high-dose and frequent administration of FVIII, a costly and
inconvenient procedure. Thus, before applying Tregitopes in
future clinical studies, we wished to evaluate their immunoge-
nicity. We emulsified a mixture of mTregitope167 and mTregi-
tope289 with IFA or CFA and immunized C57BL/6 mice. Af-
ter 2 weeks, draining inguinal and popliteal LNs were removed
and assayed for T cell responses to individual Tregitopes.
OVA323–339 peptide was used as a positive, MHC-binding con-
trol. In vitro T cell proliferation against individual peptides
(mTregitope167, mTregitope289, and OVA323–339) is summarized
in Fig. 2. As shown, mice immunized with Tregitopes in IFA or
CFA did not respond to mTregitope167, mTregitope289, or
OVA323–339 peptide in vitro. In contrast, OVA323–339 peptide-
immunized mice exhibited a robust response to only OVA323–339
peptide in vitro after immunization with either adjuvant. These
data indicate that Tregitopes have low or no immunogenicity in
vivo, even when coadministered with the strong adjuvant CFA.
These findings were also validated in BALB/c mice; similar re-
sults were obtained (Fig. 3).
To further study the immunogenicity of Tregitopes, cul-
ture supernatants from the above experiments were col-
lected and assayed for cytokine production, including IL-2,
IL-4, IL-5, IL-6, IL-10, IL-12p40, and IFN-. We observed
similar levels of IL-2 production (1 pg/ml) in samples cul-
tured with mTregitope289 (Fig. 4A, middle panel). Samples
from Tregitopes/IFA- or Tregitopes/CFA-immunized mice
did not show higher IL-2 production than OVA/IFA or
Figure 1. Tregitopes/OVA-pulsed B cells reduce anti-OVA response in
vivo. (A) LPS-activated C57BL/6 B cells were pulsed with Tregitopes,
OVA protein, or Tregitopes plus OVA protein in vitro, and then 107-
treated B cells were transferred into naïve C57BL/6 recipients. On
Day 7 postinjection, animals were immunized in a hind footpad and
the base of tail with 25 g OVA323–339 peptide (pOVA323–339) emulsi-
fied in CFA. Two weeks postimmunization, animals were killed, and
draining LNs were removed. T cell proliferation was assayed by mea-
suring IFN- production by Elispot. Cells were incubated for 48 h with
indicated concentrations of OVA323–339 peptide. Data represent mean
spots  se for four animals. This is a representative of two indepen-
dent experiments (**P0.01; *P0.05). (B) Treatment is same as A.
Sera were collected 2 weeks after immunization and analyzed by
ELISA, and ELISA plates were coated with 10 g/ml OVA protein.
Data represent mean anti-IgG titers  se for four animals.
Su et al. Immunogenicity and B cell delivery of Tregitopes
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OVA/CFA controls. When cultured with mTregitope167 in
vitro, samples from Tregitopes/IFA- and Tregitopes/CFA-
immunized mice exhibited a twofold increase in IL-2 pro-
duction compared with the OVA/IFA or OVA/CFA controls
exposed to mTregitope167, respectively (Fig. 4A, left
panel). This was not unexpected, as we used C57BL/6 mice
as recipients, whose H-2b MHC background better matches
the binding restriction of mTregitope167. On the other
hand, when cultured with OVA323–339 peptide, Tregitopes/
IFA and Tregitopes/CFA produced much less IL-2 than the
OVA/IFA and OVA/CFA controls, suggesting that the ob-
served IL-2 production in vitro was antigen-specific (Fig. 4A,
right panel).
When cultured in the presence of OVA323–339 peptide, lym-
phocytes from OVA/IFA- and OVA/CFA-immunized mice se-
creted IFN- at 25 and 600 pg/ml, respectively. In contrast,
neither the Tregitopes/IFA nor Tregitopes/CFA groups pro-
duced IFN- under these conditions (Fig. 4B, right panel).
When cultured with mTregitope167, cells from Tregitopes/
IFA-immunized mice did not produce IFN-, and even samples
from mice immunized with Tregitopes/CFA only produced
IFN- at 10 pg/ml (Fig. 4B, left panel), suggesting that
Tregitopes are weak antigens and do not induce a Th1 re-
sponse in vivo. None of the samples produced IFN- when cul-
tured in vitro in the presence of mTregitope289 (Fig. 4B, mid-
dle panel). As shown in Fig. 4C, neither Tregitopes/IFA nor
Tregitopes/CFA treatment induced IL-10 production under in
vitro culture conditions, suggesting that no Th2 response was
present. In addition, no IL-4, IL-5, IL-6, or IL-12p40 was de-
tected from supernatants in any groups (data not shown).
Finally, we validated the immunogenicity of Tregitopes at
the transcription factor level. C57BL/6 mice were immunized
with a mixture of mTregitope167 and mTregitope289 or
OVA323–339 in IFA; PBS/IFA-immunized mice were used as a
normalization control. Two weeks later, lymphocytes from the
draining LNs were cultured with a mixture of mTregitope167
Figure 2. Tregitopes elicit a
low or nonexistent immune
response in vivo. Tregitopes
(mixture of mTregitope167
and mTregitope289) or
OVA323–339 peptide were
emulsified with IFA (A) or
CFA (B) and then injected
in one footpad of C57BL/6
mice. Two weeks later,
draining popliteal and in-
guinal LNs were removed
and assayed for T cell prolif-
eration by [3H] thymidine
incorporation. Cells
(5105) were seeded/well
in 96-well plates in the pres-
ence of mTregitope167,
mTregitope289, or OVA323–339
peptide. Forty-eight hours
later, cells were pulsed with
1 g/ml [3H] thymidine
and cultured for another
16–20 h. Data represent
mean cpm  se for four
animals. This is a represen-
tative of two independent
experiments.
Figure 3. Tregitopes have a low or no immunogenicity in BALB/c
mice. BALB/c mice were treated with IFA-emulsified Tregitopes (mix-
ture of mTregitope167 and mTregitope289) or OVA323–339 peptide.
Two weeks later, T cell proliferation assay was performed (same as in
Fig. 2). Cells (5105) were seeded/well in 96-well plates in the pres-
ence of mTregitope167/mTregitope289 or OVA323–339 peptide. Forty-
eight hours later, cells were pulsed with 1 g/ml [3H] thymidine and
cultured for another 16–20 h. Data represent mean cpm  se for
four animals. This is a representative of two independent experiments.
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and mTregitope289 or OVA323–339, respectively. After 48 h,
cells were collected, and RNA samples were extracted for assay
by real-time PCR. We evaluated the expression of T-bet,
GATA3, RORt, and Foxp3, representing Th1, Th2, and Th17
cells and Tregs, respectively. As shown in Fig. 5, lymphocytes
from mice immunized with Tregitopes only exhibited a mod-
est increase in expression of T-bet when in vitro-stimulated
with Tregitopes, compared with those stimulated with OVA323–339
peptide. In contrast, cells from OVA323–339 peptide-immunized
mice exhibited a robust up-regulation of T-bet expression un-
der the condition of OVA323–339 stimulation. These results are
consistent with the IL-2 and IFN- production and the cell
proliferation data. We also detected an up-regulated expres-
sion of FoxP3 in LN cells from Tregitope-treated mice when
cultured in vitro with Tregitopes compared with the OVA323–339
condition (P0.06). No difference has been found in the ex-
pression of GATA3 and RORt under our experimental condi-
tions. Together, these data confirmed that Tregitopes have
limited, if any, immunogenicity.
DISCUSSION
Here, we have demonstrated that Tregitopes, which have
promising potential as immune-regulatory therapeutics, have
little or no immunogenicity in vivo. We also studied the ad-
ministration route of Tregitopes and found that B cell delivery
of Tregitopes very effectively suppressed the immune response
to the accompanying antigen in vivo. This study suggests that
effective antigen presentation by professional APCs, such as B
cells (or DCs), in the presence of immune-activating adjuvants,
such as IFA or CFA, may be an effective means of delivering
Tregitopes in future research applications. As neither IFA nor
CFA is approved for human therapeutic use, and peptide ther-
apies are notoriously difficult to formulate, other means of
delivering the Tregitopes to APCs will be necessary to acceler-
ate their path to the clinic.
A wide range of strategies that reduce the activity of autore-
active effector CD4 T cells and increase Tregs in number or
potency have been examined. Some have been applied as ther-
apeutics and are undergoing clinical trials [28]. As Tregs play
an essential role in immune regulation, induction or expan-
sion of antigen-specific Tregs is one of the major directions
under consideration for establishing antigen-specific tolerance.
However, because of the lack of knowledge regarding the
epitope specificity of Tregs, no effective means of achieving
this goal has been developed thus far.
We reported previously that several Tregitopes, which are
promiscuous MHCII epitopes for T cells, were able to activate
Figure 4. Tregitopes elicit low or no Th1 and Th2 cytokine
production. Mice were treated as described in Fig. 2. Supernatants
were collected from 2 g/ml antigen-treated cells after 48 h cell cul-
ture. Samples were examined for the production of IL-2 (A), IFN-
(B), and IL-10 (C) and IL-4, IL-5, IL-6, IL-12p40, and TGF- (data not
shown). Data represent mean concentration  se for four animals.
This is a representative of two similar experiments.
Figure 5. Tregitopes have a modest effect on the
expression of T-bet mRNA. C57BL/6 mice were
immunized with Tregitopes (mixture of mTregi-
tope167 and mTregitope289; n5), OVA323–339
peptide (n4), or PBS (n1) in IFA. Two weeks
later, draining popliteal and inguinal LNs were re-
moved, and cells were cultured with a mixture of
Tregitopes or OVA323–339 peptide. Forty-eight hours
later, RNA samples were extracted for detecting the
expression of T-bet, GATA-3, RORt, and Foxp3.
Individual samples were normalized to the detected
Ct values of control gene GADPH, and data were
presented as the relative expression to the PBS/IFA
control. Data represent mean  se. This is a repre-
sentative of two similar experiments (**P0.01).
Su et al. Immunogenicity and B cell delivery of Tregitopes
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CD4FoxP3 nTregs in human PBMCs in vitro and in vivo
[17, 20]. Since that time, the potential applications of Tregi-
topes have been investigated in most of the animal models for
allergy and autoimmune diseases. In a T1D model, we demon-
strated that when NOD female mice were treated s.c. with
Tregitopes in IFA at disease onset, Tregitope treatment re-
versed the hyperglycemia significantly [20]. Elyaman and col-
leagues [29] found that Tregitopes suppress EAE in a mouse
model. In an allergy model, coadministration of OVA protein
with Tregitopes reduced the allergic response to OVA and in-
duced Tregs [Mazer and Massoud, personal communication,
June, 2011]. Other collaborators have found that Tregitopes
suppressed CD8 T cell responses or reduced clinical scores in
hemophilia B gene therapy [Mingozzi et al. (unpublished re-
sults)] and were effective in a model for Crohn’s disease [30].
Based on these preliminary studies, which have been summa-
rized recently [19], we believe that Tregitopes have significant
potential to translate into clinical use as an immuno-regulatory
therapeutic.
The immunogenicity of protein therapeutics, including hu-
manized mAb, reduces their efficacy in clinical applications
[31]. Some of these protein therapeutics are immune-activat-
ing; thus, we were curious as to whether Tregitopes would be
immunogenic under inflammatory circumstances. Several in-
trinsic and extrinsic factors determine the immunogenicity of
a protein therapeutic, including its origin (self vs. nonself), T
cell epitope content, formulation, aggregation, post-transla-
tional modification, route of delivery, and patient HLA [31].
As Tregitopes are short peptides, the intrinsic factors (such as
post-translational modification) that contribute to immunoge-
nicity are less likely to be influential. Two common delivery
routes of therapeutics in patients are i.v. and i.m. injection.
The former favors tolerance, and the latter is prone to induc-
ing immune responses. Therefore, we immunized mice with
Tregitopes s.c. in the presence of CFA or IFA as a stringent
test for immunogenicity, as both are well-known adjuvants for
inducing immune responses in mice. However, even under
such conditions, Tregitopes elicited little to no T cell re-
sponse. In addition, we did not find significant Th1 and Th2
cytokine production, with the exception of Tregitopes/CFA-
immunized mice, in which T cells produced minimal IFN-.
To our surprise, we did not find any IL-10 production from T
cells isolated from Tregitope-treated animals, as opposed to
OVA peptide-immunized mice. We could not exclude the role
of IL-10 played in Tregitope-induced immune suppression, as
Tregitopes might stimulate the IL-10 production by APCs,
such as B cells. However, our current data suggest that produc-
tion of Th2 cytokines by T cells may not be a major mecha-
nism by which Tregitopes function under this protocol. In-
deed, we did not find any increase in GATA3 expression as a
result of Tregitope treatment. Whether Tregitopes treatment
increases the IL-10 production by APCs requires further verifi-
cation, as it has been established that gene therapy with IgG
fusion proteins requires host IL-10 production [32].
Our goals are to deliver Tregitopes effectively and to induce
Tregs specifically. To achieve them, we have tested different
protocols, including IFA emulsification, liposome delivery,
multiple injections, different sites of injection, and coadminis-
tration or fusion with a target antigen [19]. In this study, we
investigated whether B cells could effectively deliver Tregitopes
to induce tolerance. B cells were chosen as Tregitope carriers,
as our group has a successful record using them as tolerogenic
APCs. When retrovirally transduced with an antigen-IgG fu-
sion, B cells are able to induce antigen-specific tolerance in
vivo [13, 14]. This gene therapy strategy has shown efficacy in
multiple models of autoimmune diseases and hemophilia A
inhibitor formation [15, 23, 24]. We have also shown that
when pulsed in vitro with a target antigen fused with a TAT
peptide, B cells are also capable of inducing tolerance to the
target antigen. This protein therapy strategy has shown efficacy
in EAE and T1D [33]. Therefore, we proposed that Tregitopes
can be delivered with an accompanying antigen by B cells for
tolerance induction. Indeed, our results have shown that B
cells pulsed in vitro with Tregitopes alone or Tregitopes com-
bined with OVA protein were able to reduce anti-OVA T cell
and antibody responses in vivo, with codelivery exhibiting a
stronger effect. Thus, our findings indicate that B cell delivery
may be an effective delivery route for Tregitopes, although
alternative routes may be more feasible for translation to the
clinic. Moreover, our data could provide insights into the
mechanisms of tolerance induction by gene therapy and/or
IVIg infusion. We have shown previously that B cell presenta-
tion of peptide-IgG by the MHCII pathway is critical for toler-
ance induction and that the tolerogenic properties of peptide-
IgG-transduced B cells depend on Tregs [15, 34, 35]. More
importantly, although it is not essential for tolerance induc-
tion in our gene therapy system, IgG significantly enhances
the degree of tolerance and prolongs the hyporesponsive
state [36, 37]. Thus, we propose that the presence of Tregi-
topes in the IgG facilitates the induction of Tregs in vivo.
As a result, Tregs induced by peptide-IgG gene therapy or
therapeutic IVIg might be a result of the presence of Tregi-
topes in the Fc region. We will examine this hypothesis by
generating a fusion protein containing target antigens
linked to Tregitopes and transferring this fusion construct
in vivo to test tolerance induction to the target moiety.
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